title: Sustained molecular response with nilotinib in imatinib-intolerant chronic myeloid leukaemia with an e19a2 BCR-ABL1 fusion.
authors.affiliation: Cancer Molecular Diagnostics, St. James's Hospital, Dublin, Ireland.
authors.forename: Mireille
authors.initials: M
authors.lastname: Crampe
authors.affiliation: Department of Haematology, Beaumont Hospital, Dublin, Ireland.
authors.forename: Jennifer
authors.initials: J
authors.lastname: Garry
authors.affiliation: Cancer Molecular Diagnostics, St. James's Hospital, Dublin, Ireland. Electronic address: slangabeer@stjames.ie.
authors.forename: Stephen E
authors.initials: SE
authors.lastname: Langabeer
authors.affiliation: Department of Haematology, Beaumont Hospital, Dublin, Ireland.
authors.forename: Philip T
authors.initials: PT
authors.lastname: Murphy
mesh_terms: D005260:Female; D016044:Fusion Proteins, bcr-abl / Q000235:genetics* / Q000378:metabolism; D006801:Humans; D000068877:Imatinib Mesylate / Q000627:therapeutic use*; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000188:drug therapy* / Q000235:genetics*; D008875:Middle Aged; D011743:Pyrimidines / Q000627:therapeutic use*; D012333:RNA, Messenger / Q000235:genetics / Q000378:metabolism
chemical_list: C581634:BCR-ABL1 fusion protein, human; D011743:Pyrimidines; D012333:RNA, Messenger; D000068877:Imatinib Mesylate; D016044:Fusion Proteins, bcr-abl; C498826:nilotinib
keywords: Chronic myeloid leukaemia; Imatinib; Intolerance; Nilotinib; e19a2